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Review Letter 
1. Introduction 
Since p~iI~Iicat~on f the first review tetter [I J on 
hormone receptor interactions in January 1976 
progress in the field has been rapid. Recent advances 
now make it possible to discuss hormone-receptor-- 
ade~ylate-cyciase interactions and their control in 
more definitive terms. This has encouraged us to 
present some further thoughts on the same topic. A 
comprehensive coverage of the literature was not 
intended and certainly the selection of topics is 
strongly biased by the authors interests. 
A large number of hormones and neurotrans- 
mitters activate adenylate cyciase (EC 4.6.1.1) in 
the course of eliciting their physiological response. 
In each case the hormone or the neurotransrnitter 
interacts with a specific receptor at the outer surface 
of the cell which, in turn, interacts with the catalytic 
moiety of adertylate cyclase that faces the inside of 
the cell and causes its activation: 
ATP + Mg2* 
hormone or neurotransl~itter 
_.-_._--_-.--_-----_.----d 
receptor and adenyiate cyclase CAMP + PPi 
Sutherland and his colleagues have already sug- 
gested that the receptor-eyclase system is a regtllatory 
enzyme and have pointed out the analogy between 
adenylate cyclase and aspar-tate transcarb~oylase 
Abbreviations: DOPC, dioleoylp~~ospl~atidyic~o~ine; DMPC, 
d~rnyristoy~p~osp~at~dy~c~ol~~e; Gpp(NH)p, guanosine S- 
f&y-imino) triphosphate; GTPrS and GDP@. guanosine 5’- 
(3-thio) trip~osp~ate and guanosine 5’-(2-thio) diphosphate, 
respectively; CAMP, adenosine 3’,S’-cyclic monopllosphate 
with the receptor as regulatory unit in the case of 
adenylate cyclase /2]. Recent evidence by Schramm 
and others indeed demonstrates that receptor and 
cyclase moiety are separate proteins [3--71. More- 
over, it became apparent since the original studies of 
Rodbell and his colleagues [8-l l] that an additional 
regulator, the transducer, plays a decisive role in the 
processing of the hormonal signal. Although binding 
of the hormone or the neurotransmitter is an 
obligatory event ]12--141 the nucleotide GTP must 
also be present for Ilor~~loile~il~duced activation of 
adenylate cycfase to occur. The requ~re~?~ent for GTP 
was not recognized for quite a while, because the sub- 
strate ATP used in the cyclase assay is often con- 
taminated with enough GTP to saturate the regulatory 
site [ 151. When ATP free of CTPis used in the cyclase 
assay, the dependence of cyclase activity on GTP can 
readily be demonstrated in most cases, 
2. The problems 
The three problems in the forefront today are 
therefore the role of GTP, the mode of coupling 
between receptor and adenylate cyclase and the 
regulatory control over these processes. 
3. The role of GTP 
It is now generally accepted that GTP functions as 
an intracelluiar effector which interacts with another 
separate regulatory moiety and activates the enzyme 
synergisticahy with the hormone (for references, 
see [ I.61 ). GTP anaiogues such as Gpp(N~)p, GTPyS 
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and Gpp(CHz)p activate adenylate cyclase in a quasi- 
irreversible fashion and, in the presence of hormone, 
induce the formation of a stable, high activity state 
(cf. [ 161 and [ 17-301). Detailed kinetic analysis of 
the /3-adrenergic receptor-dependent adenylate cyclase 
activation [ I2- 14,3 1,321 indicated that the 
/3-adrenergic agonist facilitates activation by the 
guanyl nucleotide. The efficacy of the P-agonist has 
the following order: 
I-isoproterenol = I-epinephrine = I-norepinephrine 
> dopamine > phenylephrine >> metanephrine 
Antagonists such as I-propanolol have no effect. Aside 
from a role of GTP in the activation of adenylate 
cyclase, effects of guanyl nucleotides on the inter- 
action of receptors with agonists have also been 
described. Thus, GTP and its analogues were found to 
reduce the affinity of glucagon for its receptor [33]. 
Similarly, GTP was shown in two cell types to reduce 
the affinity of fl-adrenergic receptors towards 
P-agonists but not towards P-blockers [34-361. These 
effects of guanyl nucleotides were attributed to a 
receptor-linked nucleotide site which may be different 
from the activating site [37]. The evidence for the 
existence of such a second site, however, is as yet 
circumstantial. 
3 .l . The GTP binding protein 
The hypothesis [16,17] that the guanyl nucleotide 
regulatory site represents a separate protein was 
recently verified [18,38] . GTP binding proteins could 
be separated by affinity chromatography from the 
cyclase catalytic unit by treating Lubrol PX-solubilized 
pigeon erythrocyte membrane proteins with a GTP-~ 
Sepharose matrix. These nucleotide-binding proteins 
can be dissociated specifically from the GTP-matrix 
by Gpp(NH)p or GTP. Upon addition to a cyclase 
preparation deprived of guanyl nucleotide binding 
proteins, Gpp(NH)p- and NaF-stimulated adenylate 
cyclase activity is regenerated. The guanyl nucleotide 
binding proteins isolated from pigeon erythrocyte 
membranes are capable of activating rabbit myo- 
cardial adenylate cyclase preparations depleted of 
guanyl nucleotide binding proteins, suggesting that 
this regulatory protein is a universal component of 
adenylate cyclase systems and might be able to 
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couple with the catalytic unit from other species. The 
evidence available at present indicates that in pigeon 
erythrocyte membranes, among several GTP binding 
proteins, one with mol. wt 42 000 is the guanyl 
nucleotide regulatory unit which is involved in cyclase 
activation [ 18,381. That this protein is the GTPase 
responsible for the catecholamine-activated GTPase 
activity discovered by Cassel and Selinger [39] in 
turkey erythrocyte membranes was made probable 
by the action of cholera toxin on adenylate cyclase 
activity in avian erythrocyte membranes. However, 
the final proof will require the complete purification 
of the protein. 
4. The action of cholera toxin 
A variety of mammalian cells and membranes 
derived therefrom exhibit increased adenylate cyclase 
activity subsequent to treatment with cholera toxin 
and NAD’ [40,41]. It was suggested [42] and sub- 
sequently shown [43] that cholera toxin inhibits the 
GTPase step, thus increasing the steady state con- 
centration of the activated form of adenylate cyclase 
in the presence of hormone and GTP (fig. 1). A 
molecular basis for this effect was recently provided 
when it was shown that cholera toxin-induced activa- 
tion of adenylate cyclase is correlated with ADP- 
ribosylation of the 42 000 mol. wt guanyl nucleotide 
binding protein [44,45] and inhibition of the GTPase 
step [43]. Consequently GTP becomes as effective as 
nonhydrolyzable GTP analogs. On reversal of ADP- 
ribosylation, GTP activation is likewise reversed [44]. 
GDP 
EGDP 
InactIve 
\ 
E&awlp E’,TP 
actwe oct1ve 
y-Cholera toxin 4 
pi 
Fig.1. Activation-deactivation of adenylate cyclase: the 
GTP-cycle according to Cassel and Selinger [43]. 
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5. Mechanism of adenylate cyclase activation 
Conversion of adenylate cyclase to its activated 
state requires simultaneous binding of agonist and 
guanyl nucleotide to their respective sites. Termina- 
tion of hormonal activation occurs when GTP is 
hydrolyzed at the guanyl nucleotide regulatory site to 
GDP and Pi. In turkey [39] and pigeon erythrocytes 
(Cassel and Pfeuffer, unpublished) the P-receptor- 
dependent GTPase activity could be measured directly. 
Indeed, the hydrolysis step per se does not require 
the continued presence of the hormone at the recep- 
tor [46,47], but enzyme activation occurs only when 
a new molecule of GTP enters the guanyl nucleotide 
binding site and the GDP produced in the hydrolysis 
step is discharged from this site. Thus GTP+GDP 
exchange only occurs when the receptor is occupied 
by the hormone [48]. This sequence is interrupted 
when a non-hydrolyzable GTP analogue is bound at 
the guanyl nucleotide site because the hydrolytic 
step does not take place [13,14,49] and consequently 
the enzyme remains in the active state E’. It is impor- 
tant to note therefore that the only function of the 
hormone is to facilitate GTP*GDP exchange [48] 
and that the GTP form of the binding protein associates 
with the catalytic moiety whereas the GDP form can 
not form active holoenzyme [38] (see fig.l). 
When hormone and GTP are saturating, the 
system at steady state is described by the equation: 
GTP, hormone, k,, 
E \~ _.___~- E’ (1) 
%I, 
Thus, the total enzyme concentration in the mem- 
brane [ET] is: 
LET] = [El + [E’l (2) 
and at steady state: 
k,, PI = k,, [E’l (3) 
Inserting (2) into (3): 
[E’l = LETI /[I +ko~/konl (4) 
Thus, the fraction of the total cyclase pool in its 
active form is determined by the ratio koff/k,, 
[46,47]. For the turkey erythrocyte /3-adrenergic- 
dependent adenylate cyclase, k,, and k,, have been 
measured directly: k,, was determined under con- 
ditions where k,, = 0 by following the rate of 
adenylate cyclase activation at saturating concentra- 
tions of I-epinephrine and Gpp(N1H)p [ 12.131. Since 
Gpp(NH)p cannot be hydrolyzed. all the cyclase 
molecules are eventually converted to the activated 
form and [E’] = [ET]. This occurs in the range of 
k,, = 0.4.- 1 .O min-’ at 37°C. k,, was also mcasurcd 
directly in the turkey erythrocyte system by two 
independent means: one method involved the 
measurement of GTP hydrolysis at the regulatory site 
[39] ; the second method involved the measurement 
of the rate of decay of the activated state E’ to the 
inactive state E. In the latter case the enzyme was 
preincubated with hormone, GTP? and non-radioactive 
ATP; and decay was initiated by simultaneous addi- 
tion of [o(-~~P] ATP and of an excess of B-antagonist 
[46,50] to block the reconversion (activation) of E 
to E’. Under these conditions c-[~‘P]AMP will be 
produced until E’ is exhausted. The time course of 
c-[~~P]AMP formation therefore is the time course 
of decay of E’ to E from which k,, can be derived 
[47,50]. When a suitable antagonist is not available, 
the experiment can be performed with GDP/3S [Sl ] 
which replaces GDP at the regulatory site but because 
of its tight binding, prevents exchange with GTP. The 
latter quenching method can be applied to any 
adenylate cyclase system, including preparations 
where measurements of specific hormone-dependent 
GTPase activity over the background of nucleoside 
triphosphatase activity are not feasible. Using eq. (4) 
one can compare theoretical and experimentally 
observed activity ratios. Such a comparison has 
actually been carried out for the turkey erythrocyte 
P-receptor system, and the correspondence was 
satisfactory, [ 14,46,47,52] affirming that the simple 
two state system described in cq. (l- 4) is adequate. 
6. The mode of coupling 
Little is known about the organization of the 
multi-component adenylate cyclase system - which is 
composed of at least three separate components: the 
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receptor, the GTP-binding protein and the catalytic 
unit ~ within the membrane. In this context the 
stoichiometry and the mode of coupling between the 
components are of main interest. In principle, four 
modes of coupling are plausible: (see [25,53] and for 
further references [52] ). In the precoupled model (I), 
enzyme and receptor are permanently coupled like 
regulatory and catalytic subunits in aspartate trans- 
carbamoylase. In this case enzyme activation can be 
described by the upper scheme of fig.2. The model 
predicts non-cooperative P-agonist and P-antagonist 
binding. It also predicts that conversion to the 
permanently active state, in the presence of hormone 
and Gpp(NH)p is first order. In the dissociation 
model (II), enzyme and receptor are only attached to 
each other in the absence of a P-agonist. Subsequent 
to hormone binding, receptor and enzyme separate 
concomitantly with enzyme activation. This is 
analogous with CAMP-dependent protein kinase 
activation [54]. This model predicts negatively 
cooperative fl-adrenergic ligand binding 
I. PRE -COUPLED 
R R’E’GTp\ 
RE k, l+R.E-GTP+ l+R.E’GTP 
% H.REH .Ik4 
H’REtGDPtPi 
[REI, 
[H.R.E\GTPl= - 
I+k4 
k3 
Iv. COLLISION COUPLING 
H.R -(HR-E,GTPs H.R.E:GTP) k H.RtE’GTP 
k,.EGTP 
hi 41 - J 
k4 
HtR 
LETI 
EtGCF’tPI 
[E’.GTP~= k4 
“k,lRTl 
Fig.2. The precoupled model and the collision coupling model 
for receptor to adenylate cyclase coupling. R, receptor; E, 
enzyme; E’, activated enzyme; [ET], the total enzyme con- 
centration; RE, the total receptor-enzyme concentration. 
The formulas for each of the models describe the maximal 
concentration of active cyclase in the presence of saturating 
concentrations of hormones and GTP. Further explanations 
are given in the text. 
and non-first order kinetics of enzyme activation in 
the presence of P-agonist and Gpp(NH)p. In the 
floating receptor model (III), hormone, receptor and 
enzyme are in equilibrium, and the fraction of 
enzyme combined with the receptor is dependent on 
agonist concentration. This model, like model II, 
predicts negatively cooperative hormone binding and 
complex non-linear kinetics of enzyme activation. 
The collision coupling model (IV), is described in the 
bottom scheme of fig.2 and predicts first order 
kinetics of enzyme activation by hormone and 
Gpp(NH)p and non-cooperative ligand binding. One 
of us (A.L.) has recently presented evidence (for 
technical details and additional references consult 
[52] ) with the turkey erythrocyte P-receptor- 
dependent cyclase, indicating that coupling between 
receptor and enzyme can be described by the collision 
coupling model. The evidence is as follows: binding 
of p-antagonists and P-agonists is non-cooperative and 
the kinetics of enzyme activation in the presence of 
Gpp(NH)p is first order. Although binding as well as 
kinetic data could be equally well accounted for by 
either model I or IV, a distinction between these 
models was possible on the basis of the following 
argument: model I predicts that in the presence of 
Gpp(NH)p (koff = 0), the rate constant of enzyme 
activation (k,,) is independent of receptor concen- 
tration whereas the maximal number of activated 
catalytic units is proportional to the receptor con- 
centration. 
The ‘collision coupling’ model (IV) predicts the 
opposite: in this case the rate constant of enzyme 
activation is proportional to the receptor concentra- 
tion whereas the maximal number of catalytic units 
that can eventually be activated is independent of 
receptor concentration. This prediction was scrutinized 
experimentally with an irreversible fl-adrenergic 
blocker. The results were compatible with the 
‘collision coupling’ mechanism in the case of 
/3-adrenergic receptor, whereas in the case of the 
adenosine receptor the precoupled model described 
the data more adequately (cf. [52] ). 
7. The influence of membrane fluidity [ 55-681 
Two effects of an increase in membrane fluidity 
have recently been described by us [59,60] and 
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[61--631. In membranes of Chang liver cells in 
culture made more fluid by fusion with DMPC and 
DOPC vesicles /3-receptors disappeared at 37°C (above 
the phase transition) and the specific activity of 
isoproterenol-stimulated adenylate cyclase (in the 
absence of Gpp(NH)p) declined. At 17°C (below the 
phase transition) no changes were observed in the 
DMPC-enriched membrane: but as was to be expected, 
receptors and activity were still decreased in the 
DOPC-enriched membrane at 17°C which is still 
above phase transition for this membrane. The decline 
of activity as a consequence of membrane fluidity 
was most pronounced with the receptor-dependent 
isoproterenol-stimulated adenylate cyclase and with 
(Na’, K+)-activated ATPase. Functions of adenylate 
cyclase independent of the receptor, such as Gpp- 
(NH)p- and NaF-dependent cyclase activities declined 
much less as a function of membrane fluidity. We 
therefore concluded [59,60] that lateral diffusion of 
membrane proteins must be restricted and order 
maintained in fluid membranes to allow spatially 
organized enzyme systems which catalyze vectorial 
reactions to couple in a two dimensional space. Thus, 
when the coupling efficiency of the remaining recep- 
tors which were not dislodged or ‘sunk’ in the 
fluidized membrane was measured, it was found to be 
equal to or greater than that in the normal membrane. 
Thus, so long as spatial order is maintained, fluidity 
actually increases the rate of coupling between recep- 
tor and adenylate cyclase. The latter observations 
were therefore in agreement with the observation 
[6 l-631 that insertion of cis-vaccenic acid into 
turkey erythrocyte membranes [66] caused a progres- 
sive increase in membrane fluidity and a concomitant 
increase in the rate constant (k,,) of cyclase activa- 
tion by P-agonist (but not by adenosine). Recently 
Schlessinger et al. could directly observe with a sen- 
sitive video--microscopic system aggregation and 
internalization of insulin- and epidermal growth 
factor-receptor complexes in 3T3 fibroblasts [68a]. It 
should therefore be feasible also to study the fate of 
P-receptors by a similar experimental approach. Such 
information might give some insight into the molec- 
ular order of multicomponent systems in membranes 
which undergo association-dissociation reactions in 
the course of activation-deactivation [68,38]. 
Nevertheless, both these independent observations, 
with the Chang liver cells in culture and with turkey 
erythrocytes, are consistent with a collision coupling 
mode for P-receptor-adenylate cyclase coupling. It 
should be noted that the commited step which leads 
to activation in the collision coupling model is the 
encounter of HR and E. since k,>>k,: 
H+R=HR+E.GTP- 
KI-I 
F [HRE GTP=HRE’ GTP] 
4 
ks ki 
--wHR t E’ . GTP+E t GDP + Pi 
Under physiological conditions in the presence of 
saturating concentrations of GTP, the activated form 
E’ will decay to its inactive form concomitantly with 
the hydrolysis of GTP at the regulatory site. In the 
presence of Gpp(NH)p, k6<<k5 and k6 becomes 
rate limiting preventing the decay of E’+E. 
8. Future directions 
There are consequences of the collision coupling 
mode for hormonal activation of adenylate cyclase 
worth discussing. Firstly, only a fraction of the total 
adenylate cyclase pool may be in the active state 
when the physiological activator GTP is present. 
Secondly, the apparent first order rate constant of 
activation (but not the maximal activity attainable in 
the presence of Gpp(NH)p) is linearly dependent on 
total receptor concentration. It is thus tempting to 
speculate that physiological mechanisms come into 
play either to control the collision rate for example 
by modulating membrane fluidity and/or to control 
the GTPase reaction. In the former case, mechanisms 
like those catalyzed by methyltransferases which 
convert phosphatidylethanolamines into phosphatidyl- 
cholines [69] and control of membrane fluidity by 
cytoskeletal contractile elements are attractive can- 
didates [70--721. In the latter case a physiological 
covalent amplification cascade deserves attention 
since covalent ADP-ribosylation by the unphysiological 
ADP-ribosyltransferase of cholera toxin has actually 
been demonstrated to inhibit this step [43,44]. The 
ADP-ribosyltransferase in turkey erythrocyte cytosol 
recently discovered by Moss and Vaughan might play 
a physiological role [73]. 
In any event, further progress will require con- 
tinuing efforts towards purification of the adenylate 
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cyclase system. The SOOO-fold purification of canine 
myocardial adenylate cyclase by hydrophobic and 
affinity chromatography achieved by Homey et al. 
[74] and the identification of the P-receptor sub- 
unit [75] are a hopeful beginning. 
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